Nectin Therapeutics, a Peregrine Ventures portfolio company, was selected for funding through the European Innovation Council (EIC) Accelerator, receiving a €2.5 million grant to support the development of NTX1088, its first-in-class anti-PVR immuno-oncology therapy. Nectin was selected from more than 1,000 proposals as one of 42 companies awarded funding in the highly competitive EIC Accelerator round. The company also became eligible for potential equity financing of up to €15 million. The funding supports the continued clinical development of NTX1088 and Nectin’s efforts to advance new treatment options for patients with difficult-to-treat cancers.
Official source: European Commission, CORDIS
